Lungs in Action Program

LFA_Lungs in Action Logo_0616_CMYK_LLungs in Action is a safe, enjoyable, low cost ongoing exercise program specially developed for people who have competed rehabilitation to maintain their health and fitness gains.

The benefits of pulmonary rehabilitation, such as improvements in exercise performance, and quality of life, have been shown to decline gradually over 6-12 months after completing these programs if people do not keep up with a regular exercise program1.

People with stable chronic lung conditions who have completed a pulmonary rehabilitation program, in addition to people with NYHA Class II and III heart failure who have completed heart failure rehabilitation can be referred into these weekly classes.

All Lungs in Action classes are run by exercise professionals who have been specially trained in exercising people with chronic lung conditions and heart failure. Lungs in Action classes are suitable for people using supplemental oxygen and/or walking frames. And there are seated options for all exercises if required.

To find out more on Lungs in Action like referral process and edibility, or to find your nearest location visit www.lungsinaction.com.au.

Once you have completed pulmonary rehabilitation it is recommended that you continue to maintain the gains by doing Lungs in Action which is a  pulmonary maintenance exercise. Ian Venamore lives with COPD and enjoys attending Lungs in Action classes twice a week.

Watch this video to learn more about pulmonary maintenance exercise and Ian’s story.

Remember, it is a requirement to complete pulmonary and/or heart failure rehabilitation prior to commencing Lungs in Action. To view pulmonary rehabilitation program locations click here, or contact us: 1800 654 301 for more information.

 

References:

1. Cockram J, Cecins N, Jenkins S. Maintaining exercise capacity and quality of life following pulmonary rehabilitation. Respirology (2006) 11, 98-104

Foundation Partners:
Principal Partners:

Novartis Pharmaceuticals

AZ Logo 150px
Supporting Partners: GlaxoSmithKline.